Surufatinib plus paclitaxel as second-line therapy for advanced gastric cancer: a single-arm, phase 2 clinical trial
Authors
- Ying-Jie Su
- Xiaolin Lin (ORCID: https://orcid.org/0000-0002-2417-6284)
- Xiuying Xiao (ORCID: https://orcid.org/0000-0002-9873-0380)
- Jiujie Cui (ORCID: https://orcid.org/0000-0003-0853-7569)
- Feng Jiao
- Tao Wang (ORCID: https://orcid.org/0000-0001-6402-5571)
- Xinyi Zheng (ORCID: https://orcid.org/0000-0002-2570-5627)
- Xiuqi Wu
- Meng Zhuo
- Ting Han (ORCID: https://orcid.org/0000-0003-2550-7310)
- Xiaoxia Qiu (ORCID: https://orcid.org/0000-0003-4084-8420)
Institutions
- Renji Hospital (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Cellular Oncology
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1007/s13402-025-01127-9
- Citations
- 1
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.52